CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Trental +1 moredrug
Likely dose
Trental 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01508221
NCT01508221Phase 2Completed
CompareCT.gov

A Phase II Trial to Evaluate the Use of Trental and Vitamin E for Prophylaxis of Radiation Necrosis

University of Cincinnati·interventional·Posted Jan 11, 2012·Updated Sep 14, 2023

In Brief

A Phase 2 clinical trial evaluating Trental and Vitamin E for Brain Metastasis. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether the use of Trental and Vitamin E can help reduce the incidence of radiation necrosis (a lesion that usually occurs at the original tumor site) after radiosurgery. These two drugs are commonly used to treat radiation necrosis when it occurs but the hope is that these drugs can be used to prevent radiation necrosis from ever occurring.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Metastasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 11, 2012
Enrollment StartJun 1, 2011
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 14.5 years ago

Interventions

Trentaldrug

400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months

Vitamin Edietary

400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months